What is the Difference Between LMWH and Heparin?
🆚 Go to Comparative Table 🆚Low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) are two types of heparin drugs used to prevent and treat venous thromboembolism (VTE). They work by activating antithrombin, which inhibits blood clot formation. However, there are some differences between LMWH and UFH:
- Bioavailability and half-life: LMWH has a better bioavailability and longer half-life compared to UFH.
- Dosing: LMWH has simplified dosing and a more predictable anticoagulant response.
- Risk of heparin-induced thrombocytopenia (HIT): LMWH has a lower risk of HIT compared to UFH.
- Administration: UFH is typically given intravenously (IV), usually at a hospital, while LMWH can be injected subcutaneously at home.
- Cost: UFH is generally less expensive than LMWH.
- Duration of effects: LMWH lasts longer than UFH, and its effects are easier to predict.
- Side effects: Side effects of LMWH may be harder to reverse or remedy quickly due to its longer duration in the body.
- Bleeding risk: The risk of major bleeding is lower with LMWH compared to UFH.
Both LMWH and UFH are effective at preventing blood clots, but the choice between the two depends on factors such as patient-specific risks, costs, and administration preferences.
Comparative Table: LMWH vs Heparin
Low Molecular Weight Heparin (LMWH) and Unfractionated Heparin (UFH) are both anticoagulant drugs used to prevent and treat venous thromboembolism (VTE). However, they have some differences in their structure, molecular weight, and pharmacological properties. Here is a table summarizing the differences between LMWH and Heparin:
Property | LMWH | Heparin |
---|---|---|
Molecular Weight | Mean molecular weight of 5000 | Heterogenous mixture with chains varying from 3000 to 40,000 |
Structure | Chains with a mean molecular weight of 5000 | Chains varying from 3000 to 40,000 |
Anticoagulant Activity | Activates antithrombin, which accelerates the inactivation of coagulation enzymes thrombin (factor IIA), factor Xa, and factor IXA | Activates antithrombin, which accelerates the inactivation of coagulation enzymes thrombin (factor IIA), factor Xa, and factor IXA |
Pharmacokinetic Differences | Better bioavailability, longer half-life, and more predictable anticoagulant response | Less predictable anticoagulant response due to variable molecular weight |
Interactions | Binds less to endothelial cells and macrophages compared to heparin | Binds to platelet factor 4 (released from activated platelets) and high molecular weight multimers of von Willebrand factor |
Preparation Methods | Various methods such as alkaline depolymerization, peroxidative depolymerization, and heparinase digestion | - |
LMWHs are derived from unfractionated heparin and have a more predictable anticoagulant response due to their better bioavailability, longer half-life, and dose-independent anticoagulant activity. They are widely replacing heparin in Europe and North America. However, LMWHs should not be used interchangeably with heparin or with each other, as they have distinct pharmacokinetic and pharmacodynamic properties.
- Heparin vs Alteplase
- Anticoagulants vs Thrombolytics
- Procoagulant vs Anticoagulant
- Lidocaine vs Lignocaine
- Heme vs Hemin
- Thrombin vs Prothrombin
- Thrombocytopenia vs Hemophilia
- Von Willebrand Disease vs Hemophilia
- Pulmonary Embolism vs Venous Thromboembolism
- Anticoagulants vs Fibrinolytics
- Dibucaine vs Lidocaine
- Hemostasis vs Coagulation
- IVIG vs Plasmapheresis
- Coagulation vs Clotting
- Antiplatelet vs Anticoagulant
- Lenalidomide vs Thalidomide
- Anemia vs Hemophilia
- Thrombosis vs Coagulation
- Thrombolysis vs Fibrinolysis